Sensitivity and specificity of antibodies on necrotic tumor tissue

Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia 19104-4283, USA.
American Journal of Clinical Pathology (Impact Factor: 2.51). 12/1998; 110(5):641-6.
Source: PubMed

ABSTRACT Immunohistochemistry occasionally is used to determine the lineage of entirely necrotic tumors. However, the sensitivity and specificity of antibodies on necrotic tissue are unknown. To determine the usefulness of immunohistochemistry with necrotic lesions, a series of 24 known tumors consisting of 14 carcinomas, 2 lymphomas, 2 melanomas, and 6 sarcomas (all with extensive necrosis) was examined for reactivity with 6 cytokeratin antibodies, S100, and LCA. Carcinomas stained positively with at least 1 cytokeratin antibody in 78% of the cases. The cytokeratin antibodies with the highest sensitivity were AE1, AE1/3, S903, and PANCK. These antibodies also retained specificity for epithelial differentiation; no reactivity was observed in the 10 necrotic nonepithelial tumors. LCA retained its reactivity with necrotic lymphoma, but S100 reacted with only one third of the necrotic lesions. Unexpectedly, reactivity for LCA and S100 occurred in some necrotic carcinomas. Keratin markers can be used on necrotic tissue to determine epithelial differentiation, but the results obtained with S100 and LCA on necrotic tissue should be interpreted with caution.

16 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report on a series of 3 patients who underwent fine-needle aspiration (FNA) for clinically apparent lymphadenopathy. In all 3 cases, a diagnosis of malignancy was rendered based on cytologic findings (two metastatic squamous-cell carcinomas and one melanoma). However, initial follow-up surgical pathology reported only "extensive coagulative necrosis, no viable tumor seen." Subsequent immunohistochemical stains (cytokeratins (AE1/AE3), HMB45, S100, and Melan A) demonstrated the presence of metastatic tumor in the area of infarction in each case, thus establishing the presence of metastatic tumor and correct interpretation of the initial FNA. We conclude, based on our own experience and a few previously reported cases, that total infarction of the lymph nodes following FNA can occur, and immunohistochemistry can be helpful in clinical management.
    Diagnostic Cytopathology 08/2001; 25(2):104-7. DOI:10.1002/dc.2013 · 1.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The goal of this project is to identify genes involved in the malignant transformation of neurofibromas to malignant peripheral nerve sheath tumors using expression profiling and array-based comparative genomic hybridization. The significance of the genes will be validated on much larger numbers of cases using antibodies and in situ hybridization probes on tissue microarrays (TMAs). Genes will be further studied in in vitro experiments using cell lines from nerve sheath tumors. While the grant starting date was on Nay 1, 2003 authorization to work with human subjects was not obtained until April 1, 2004. Therefore this "annual report" will only describe the actual work performed in April 2004. Nevertheless the following progress has been made in the past year: 1. The number of cases of nerve sheath tumors available will be more than sufficient to perform the first aim of this study. 2. We have started to run expression profiling and gene microarrays on a number of nerve sheath tumors and since April 1, 2004 have analyzed six malignant peripheral nerve sheath tumors and five schwannomas. 3. We have gained much experience with in situ hybridization on TMAs. This experience will enormously benefit this project.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated 35 cases of malignant melanomas with substantial necrosis immunostained with S-100, HMB-45, Melan-A, tyrosinase, PNL2, and microphthalmia transcription factor (MITF). Staining patterns were evaluated in viable and necrotic areas of the tumors. S-100 was the most sensitive marker (97%) in the viable tumors, but necrotic areas demonstrated nonspecific staining. Viable tumors stained variably for HMB-45 (25 [71%]), Melan-A (28 [80%]), tyrosinase (30 [86%]), and PNL2 (23 [66%]). Necrotic areas focally reacted to the same antibodies. The necrotic areas that retained immunoreactivity for these markers corresponded to areas where the outline of the tumor cells could still be recognized as ghost cells on the H&E-stained section. Areas that showed complete coagulative necrosis were negative for melanoma markers. MITF variably stained in the viable tumors but was completely negative in necrotic areas. Our study demonstrated that a combination of antibodies to HMB-45, tyrosinase, and PNL2 detected melanocytic differentiation in necrotic areas in 80% of cases.
    American Journal of Clinical Pathology 06/2007; 127(5):787-91. DOI:10.1309/WKEN4ER9GXJ9GG31 · 2.51 Impact Factor
Show more